Fennec Pharmaceuticals Inc. (FENC)
USD 5.66
(-6.75%)
USD 5.66
(-6.75%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.45 Million | -18.05 Million | -14.22 Million | -15.59 Million | -9.06 Million | -7.82 Million |
| Net Income | -16.33 Million | -23.71 Million | -17.34 Million | -18.1 Million | -12.77 Million | -9.88 Million |
| Depreciation & Amortization | 221 Thousand | 132 Thousand | 14 Thousand | 402 Thousand | 64 Thousand | - |
| Deferred income taxes | 7.46 Million | - | -14 Thousand | -402 Thousand | -64 Thousand | - |
| Stock-based compensation | 5.35 Million | 4.22 Million | 4.01 Million | 2.87 Million | 3.08 Million | 1.82 Million |
| Change in working capital | -6.9 Million | 1.1 Million | -932 Thousand | -763 Thousand | 569 Thousand | 132 Thousand |
| Other non-cash items | -7.25 Million | 334 Thousand | 307 Thousand | 486 Thousand | 481 Thousand | 105 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | 2.75 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 6.75 Million | 20.73 Million | 4.97 Million | 32.28 Million | -71 Thousand | 2.34 Million |
| Debt repayment | -5.09 Million | -5 Million | -4.94 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -78 Thousand | -194 Thousand | - | - | - | - |
| Common Stock Issuance | 1.74 Million | 723.16 Thousand | -7929.61 | 33.99 Million | - | 2.21 Million |
| Other Financing Activities | -79.43 Thousand | 25.73 Million | 9.92 Million | 32.28 Million | -71 Thousand | 2.34 Million |
| Accounts receivables | -7.4 Million | -1.54 Million | - | - | - | - |
| Accounts payables | 1.41 Million | 1.61 Million | -794 Thousand | -41 Thousand | 580 Thousand | 177 Thousand |
| Inventory | -1.6 Million | -576 Thousand | - | - | - | - |
| Other working capital | 695.52 Thousand | 1.61 Million | -138 Thousand | -722 Thousand | -11 Thousand | -45 Thousand |
| Cash at beginning of period | 23.76 Million | 21.1 Million | 30.34 Million | 13.65 Million | 22.78 Million | 28.26 Million |
| Cash at end of period | 13.2 Million | 23.77 Million | 21.1 Million | 30.34 Million | 13.65 Million | 22.78 Million |
| Capital Expenditure | 2.75 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -10.56 Million | 2.67 Million | -9.24 Million | 16.69 Million | -9.13 Million | -5.47 Million |
| Free Cash Flow | -17.45 Million | -18.05 Million | -14.22 Million | -15.59 Million | -9.06 Million | -7.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -5.55 Million | 12.77 Million | -16.33 Million | -2.75 Million | -1.84 Million | -5.44 Million |
| Depreciation & Amortization | 26 Thousand | 723 Thousand | 221 Thousand | 242 Thousand | - | -73 Thousand |
| Deferred income taxes | - | - | 7.46 Million | -73 Thousand | - | 73 Thousand |
| Stock-based compensation | 925 Thousand | 1.19 Million | 5.35 Million | 857 Thousand | 865 Thousand | 2.54 Million |
| Change in working capital | -4 Million | 23.76 Million | -6.9 Million | -3.16 Million | -1.82 Million | -1.11 Million |
| Other non-cash items | 4.37 Million | 2.27 Million | -7.25 Million | 89.77 Thousand | 74.23 Thousand | 73 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | -3.37 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 246.86 Thousand | -1.12 Million | 6.75 Million | 5.83 Million | 198.81 Thousand | 514 Thousand |
| Debt repayment | - | - | -5.09 Million | -5.09 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -19 Thousand | -78 Thousand | -17 Thousand | -14 Thousand | -27 Thousand |
| Common Stock Issuance | 349.05 Thousand | 624.19 Thousand | 1.74 Million | 762.73 Thousand | 212.66 Thousand | 549.31 Thousand |
| Other Financing Activities | -102.18 Thousand | -1.75 Million | -79.43 Thousand | -17.44 Thousand | -13.84 Thousand | -8316.00 |
| Accounts receivables | -2.03 Million | -1.45 Million | -7.4 Million | -4.37 Million | -2.06 Million | -762 Thousand |
| Accounts payables | -741.07 Thousand | 1.41 Million | 1.41 Million | 853.5 Thousand | -63.86 Thousand | 58 Thousand |
| Inventory | -78.74 Thousand | 91.58 Thousand | -1.6 Million | -410.83 Thousand | -312.72 Thousand | -521 Thousand |
| Other working capital | -1.15 Million | 23.7 Million | 695.52 Thousand | 765.64 Thousand | 612.18 Thousand | 107 Thousand |
| Cash at beginning of period | 51.13 Million | 13.2 Million | 23.76 Million | 12.33 Million | 14.93 Million | 18.39 Million |
| Cash at end of period | 43.04 Million | 51.13 Million | 13.2 Million | 13.2 Million | 12.33 Million | 14.95 Million |
| Capital Expenditure | -3.37 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -8.08 Million | 37.93 Million | -10.56 Million | 861.53 Thousand | -2.59 Million | -3.43 Million |
| Free Cash Flow | -8.04 Million | 38.87 Million | -17.45 Million | -4.97 Million | -2.73 Million | -3.94 Million |
CCNTF
601699
NEA
BRY
TSL
VALIANTLAB